Last reviewed · How we verify
PERSERIS
At a glance
| Generic name | PERSERIS |
|---|---|
| Also known as | long acting risperidone |
| Sponsor | Indivior Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects (PHASE1)
- Subjective Experience Following Psilocybin (PHASE2)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- National Pregnancy Registry for Psychiatric Medications
- "Extended" (Alternate Day) Antipsychotic Dosing (PHASE4)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome (NA)
- A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PERSERIS CI brief — competitive landscape report
- PERSERIS updates RSS · CI watch RSS
- Indivior Inc. portfolio CI